SCHEMBL5752424

SCHEMBL5752424

N/N=C1\C(=O)Nc2ccc(Cl)c(Cl)c21

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 7/20 0.61
GALR3 O60755 2/20 0.40
CA1 P00915 4/20 0.36
CA2 P00918 4/20 0.36
HTR2A P28223 3/20 0.35
HTR2C P28335 3/20 0.35
HTR2B P41595 2/20 0.35
LRRK2 Q5S007 2/20 0.33
ALDH1A1 P00352 1/20 0.33
PDE7A Q13946 1/20 0.33
IDO1 P14902 1/20 0.33
CA12 O43570 1/20 0.33
CA4 P22748 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
HTR1A P08908 1/20 0.33
HTR1D P28221 1/20 0.33
HTR7 P34969 1/20 0.33
HTR3A P46098 1/20 0.33
HTR5A P47898 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6322718 0.83 CES1 (0.61) CES1GALR3HTR2AHTR2CHTR2B
SCHEMBL6316168 0.83 CES1 (0.61) CES1GALR3HTR2AHTR2CHTR2B
SCHEMBL5740387 0.80 CES1 (0.38) CES1CA1CA2LRRK2ALDH1A1
SCHEMBL9835981 0.79 CES1 (0.61) CES1GALR3IDO1TGM2
SCHEMBL5740595 0.79 CES1 (0.61) CES1GALR3IDO1TGM2
SCHEMBL7048275 0.77 CES1 (0.67) CES1GALR3CA1CA2HTR2A
SCHEMBL7048273 0.77 CES1 (0.67) CES1GALR3CA1CA2HTR2A
SCHEMBL734955 0.76 CES1 (1.00) CES1PDE7ATGM2
SCHEMBL5740135 0.75 CES1 (0.58) CES1TGM2
SCHEMBL5738059 0.71 CES1 (0.65) CES1CA1CA2ALDH1A1PDE7A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1644362-A2 INDOLINONE HYDRAZIDES AS C-MET INHIBITORS Sugen, Inc. (US) 2006-04-12 EP disclosed
US-20060009493-A1 Indolinone hydrazides as c-Met inhibitors SUGEN, INC. 2006-01-12 US disclosed
WO-2005005378-A2 INDOLINONE HYDRAZIDES AS C-MET INHIBITORS SUGEN, INC. (US) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009493-A1 Indolinone hydrazides as c-Met inhibitors MET, IGF1R, ROS1 CES1 1061/4885GALR3 982/4885CA1 2666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.